Ventolin Hfa generic
Ventolin Hfa is an aerosol drug for inhalation, owned by Glaxosmithkline. It contains the active ingredient albuterol sulfate and was first authorized for market use on 19 April, 2001. Ventolin Hfa has a total of 4 patents, out of which 2 have already expired.
When will Ventolin Hfa generic be available?
The generic version of Ventolin Hfa may become available after 26 August, 2026. This is based on the expiration date of the last patent, US7500444*PED, titled 'Actuation indicator for a dispensing device', which expires on 2026-08-26.
Ventolin Hfa uses
Ventolin Hfa, containing albuterol sulfate, is widely used in the treatment of asthma and chronic obstructive pulmonary diseases. The active ingredient, albuterol sulfate, works by relaxing the muscles in the airways and increasing airflow to the lungs, thus helping patients breathe more easily.
Ventolin Hfa patent expiration
Ventolin Hfa holds four patents, with the last one, US7500444*PED, expiring on 26 August, 2026. Two of the drug's patents have already expired. The pending generic release of Ventolin Hfa is grounded on this patent expiration date. Below are the details of the patent: